MARKET

SGHT

SGHT

Sight Sciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.10
+0.33
+3.38%
Closed 19:46 08/10 EDT
OPEN
9.93
PREV CLOSE
9.77
HIGH
10.46
LOW
9.42
VOLUME
273.08K
TURNOVER
--
52 WEEK HIGH
40.00
52 WEEK LOW
6.25
MARKET CAP
480.66M
P/E (TTM)
-6.2070
1D
5D
1M
3M
1Y
5Y
Why Sight Sciences (SGHT) Might Surprise This Earnings Season
Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 20h ago
Wall Street Analysts Believe Sight Sciences, Inc. (SGHT) Could Rally 121%: Here's is How to Trade
The consensus price target hints at a 121.5% upside potential for Sight Sciences, Inc. (SGHT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will w...
Zacks · 1d ago
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 6d ago
Bears are Losing Control Over Sight Sciences, Inc. (SGHT), Here's Why It's a 'Buy' Now
Sight Sciences, Inc. (SGHT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimat...
Zacks · 08/02 13:55
Shareholders in Sight Sciences (NASDAQ:SGHT) have lost 73%, as stock drops 12% this past week
It is a pleasure to report that the Sight Sciences, Inc. ( NASDAQ:SGHT ) is up 39% in the last quarter. But that hardly...
Simply Wall St. · 07/29 12:48
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financi...
GlobeNewswire · 07/28 12:00
Analyst Ratings for Sight Sciences
Analysts have provided the following ratings for Sight Sciences (NASDAQ:SGHT) within the last quarter:
Benzinga · 07/26 14:27
--Stifel Initiates Sight Sciences at Hold With $10 Price Target
--Stifel Initiates Sight Sciences at Hold With $10 Price Target
MT Newswires · 07/26 04:41
More
No Data
Learn about the latest financial forecast of SGHT. Analyze the recent business situations of Sight Sciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
40.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SGHT stock price target is 14.50 with a high estimate of 17.00 and a low estimate of 10.00.
High17.00
Average14.50
Low10.00
Current 10.10
EPS
Actual
Estimate
-1.46-1.10-0.73-0.37
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 66
Institutional Holdings: 24.69M
% Owned: 51.87%
Shares Outstanding: 47.59M
TypeInstitutionsShares
Increased
28
2.27M
New
16
257.72K
Decreased
15
1.02M
Sold Out
10
598.52K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.23%
Healthcare Equipment & Supplies
+2.35%
Key Executives
Non-Executive Chairman/Independent Director
Staffan Encrantz
President/Chief Executive Officer/Co-Founder/Director
Paul Badawi
Co-Founder/Chief Technology Officer/Director
David Badawi
Chief Financial Officer
Jesse Selnick
Chief Operating Officer
Sam Park
Other
Jeremy Hayden
Director
Tamara Fountain
Independent Director
Brenda Becker
Independent Director
Mack Hicks
Independent Director
Erica Rogers
Independent Director
Valeska Schroeder
Independent Director
Donald Zurbay
No Data
No Data
About SGHT
Sight Sciences, Inc. is an ophthalmic medical device company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. It sells both systems through a direct sales model.

Webull offers kinds of Sight Sciences Inc stock information, including NASDAQ:SGHT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGHT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGHT stock methods without spending real money on the virtual paper trading platform.